Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3

Interventions

Specimen Handling 648pembrolizumab 606Magnetic Resonance Spectroscopy 559Carboplatin 446Cyclophosphamide 394Cisplatin 394Biopsy 376Nivolumab 325Paclitaxel 324Gemcitabine 317Radiotherapy 295Bevacizumab 245Dexamethasone 224fludarabine 214Docetaxel 202durvalumab 194Oxaliplatin 191venetoclax 187atezolizumab 179Fluorouracil 179Rituximab 174Capecitabine 170Pemetrexed 169Radiation 164Doxorubicin 164Radiosurgery 161Ipilimumab 148Lenalidomide 143Leucovorin 139Etoposide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
68Ga-DKFZ-PSMA-11 × 90 days × Clear all
NCT03582774 2026-05-26

PSMA SRT

Jonsson Comprehensive Cancer Center

Phase 3 Active not recruiting
193 enrolled
Genitourinary

Prostatic Neoplasms

NCT06288113 2026-03-13

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Jonsson Comprehensive Cancer Center

Phase 2 Recruiting
40 enrolled
Genitourinary

Prostatic Neoplasms

NCT06216249 2026-03-10

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Jonsson Comprehensive Cancer Center

Phase 2 Recruiting
90 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡